United Therapeutics gains FDA approval for Tyvaso

07/30/2009 | American City Business Journals

The FDA cleared United Therapeutics' Tyvaso, an inhaled formulation of its injectable drug Remodulin, for pulmonary arterial hypertension. The approval comes with recommendations to make the product more patient-friendly by Oct. 31, 2010, and to test the drug for possible risks of oropharyngeal and pulmonary toxicities in patients by Dec. 15, 2013.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX